|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-1.49/-1.19
|
Enterprise Value
664.12M
|
Balance Sheet |
Book Value Per Share
1.87
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
170.28M
|
Operating Revenue Per Share
1.29
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/05/16 17:46 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product,clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is alsoavailable as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). |